Search Results - "Latinovic, Olga"

Refine Results
  1. 1

    Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy by Zhang, Yan, Du, Xuexiang, Liu, Mingyue, Tang, Fei, Zhang, Peng, Ai, Chunxia, Fields, James K., Sundberg, Eric J., Latinovic, Olga S., Devenport, Martin, Zheng, Pan, Liu, Yang

    Published in Cell research (01-08-2019)
    “…It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects…”
    Get full text
    Journal Article
  2. 2

    Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients by Weichseldorfer, Matthew, Reitz, Marvin, Latinovic, Olga S.

    Published in Pharmaceutics (27-10-2021)
    “…Combined antiretroviral therapy (cART) is treatment with a combination of several antiretroviral drugs that block multiple stages in the virus replication…”
    Get full text
    Journal Article
  3. 3

    The HIV-1 Antisense Protein ASP Is a Transmembrane Protein of the Cell Surface and an Integral Protein of the Viral Envelope by Affram, Yvonne, Zapata, Juan C, Gholizadeh, Zahra, Tolbert, William D, Zhou, Wei, Iglesias-Ussel, Maria D, Pazgier, Marzena, Ray, Krishanu, Latinovic, Olga S, Romerio, Fabio

    Published in Journal of virology (01-11-2019)
    “…The negative strand of HIV-1 encodes a highly hydrophobic antisense protein (ASP) with no known homologs. The presence of humoral and cellular immune responses…”
    Get full text
    Journal Article
  4. 4

    Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies by Weichseldorfer, Matthew, Tagaya, Yutaka, Reitz, Marvin, DeVico, Anthony L, Latinovic, Olga S

    Published in Journal of translational medicine (24-01-2022)
    “…The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that…”
    Get full text
    Journal Article
  5. 5

    Mycoplasma DnaK increases DNA copy number variants in vivo by Benedetti, Francesca, Silvestri, Giovannino, Saadat, Saman, Denaro, Frank, Latinovic, Olga S, Davis, Harry, Williams, Sumiko, Bryant, Joseph, Ippodrino, Rudy, Rathinam, Chozha V, Gallo, Robert C, Zella, Davide

    “…The human microbiota affects critical cellular functions, although the responsible mechanism(s) is still poorly understood. In this regard, we previously…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Role of Mycoplasma Chaperone DnaK in Cellular Transformation by Benedetti, Francesca, Cocchi, Fiorenza, Latinovic, Olga S, Curreli, Sabrina, Krishnan, Selvi, Munawwar, Arshi, Gallo, Robert C, Zella, Davide

    “…Studies of the human microbiome have elucidated an array of complex interactions between prokaryotes and their hosts. However, precise bacterial…”
    Get full text
    Journal Article
  8. 8

    Comparison of SARS-CoV-2 Receptors Expression in Primary Endothelial Cells and Retinoic Acid-Differentiated Human Neuronal Cells by Benedetti, Francesca, Silvestri, Giovannino, Mavian, Carla, Weichseldorfer, Matthew, Munawwar, Arshi, Cash, Melanie N, Dulcey, Melissa, Vittor, Amy Y, Ciccozzi, Massimo, Salemi, Marco, Latinovic, Olga S, Zella, Davide

    Published in Viruses (30-10-2021)
    “…SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is primarily responsible for coronavirus disease (COVID-19) and it is characterized by respiratory…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1 by Heredia, Alonso, Latinovic, Olga, Gallo, Robert C, Melikyan, Gregory, Reitz, Marv, Le, Nhut, Redfield, Robert R

    “…Vicriviroc (VCV) is a chemokine (C-C motif) receptor 5 (CCR5) antagonist with potent anti-HIV activity that currently is being evaluated in phase III clinical…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies by Latinovic, Olga S, Medina-Moreno, Sandra, Schneider, Kate, Gohain, Neelakshi, Zapata, Juan, Pazgier, Marzena, Reitz, Marvin, Bryant, Joseph, Redfield, Robert R

    Published in AIDS research and human retroviruses (01-02-2016)
    “…We have previously shown that FLSC, a chimeric protein containing HIV-1BAL gp120 and the D1 and D2 domains of human CD4, blocks the binding and entry of HIV-1…”
    Get more information
    Journal Article
  15. 15

    The HIV-1 Transgenic Rat: Relevance for HIV Noninfectious Comorbidity Research by Denaro, Frank, Benedetti, Francesca, Worthington, Myla D., Scapagnini, Giovanni, Krauss, Christopher C., Williams, Sumiko, Bryant, Joseph, Davis, Harry, Latinovic, Olga S., Zella, Davide

    Published in Microorganisms (Basel) (23-10-2020)
    “…HIV noninfectious comorbidities (NICMs) are a current healthcare challenge. The situation is further complicated as there are very few effective models that…”
    Get full text
    Journal Article
  16. 16

    Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion by Jha, Naveen K, Latinovic, Olga, Martin, Erik, Novitskiy, Gennadiy, Marin, Mariana, Miyauchi, Kosuke, Naughton, John, Young, John A T, Melikyan, Gregory B

    Published in PLoS pathogens (01-01-2011)
    “…A large group of viruses rely on low pH to activate their fusion proteins that merge the viral envelope with an endosomal membrane, releasing the viral…”
    Get full text
    Journal Article
  17. 17

    Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment by Latinovic, Olga S, Zhang, Jian, Tagaya, Yutaka, DeVico, Anthony L, Fouts, Timothy R, Schneider, K, Lakowicz, Joseph R, Heredia, Alonso, Redfield, Robert R

    Published in Current HIV research (01-01-2016)
    “…Antiretroviral (ARV) drugs targeting retroviral enzymes have been extensively employed to treat HIV-1 infection. Drawbacks of this approach include cost,…”
    Get more information
    Journal Article
  18. 18

    Structural and micromechanical characterization of type I collagen gels by Latinovic, Olga, Hough, Lawrence A, Daniel Ou-Yang, H

    Published in Journal of biomechanics (10-02-2010)
    “…Abstract In this paper we report a study where we use a novel optical tweezers technique to measure the local viscoelastic properties of type I collagen…”
    Get full text
    Journal Article
  19. 19

    Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons by Obata, Fumiko, Hippler, Lauren M, Saha, Progyaparamita, Jandhyala, Dakshina M, Latinovic, Olga S

    Published in Frontiers in molecular neuroscience (14-07-2015)
    “…Shiga toxin-producing Escherichia coli (STEC) can cause central nervous system (CNS) damage resulting in paralysis, seizures, and coma. The key STEC virulence…”
    Get full text
    Journal Article
  20. 20

    A novel small-molecule inhibitor of HIV-1 entry by Heredia, Alonso, Latinovic, Olga S, Barbault, Florent, de Leeuw, Erik P H

    Published in Drug design, development and therapy (01-01-2015)
    “…Antiretroviral therapy has transformed HIV-1 infection into a managed condition with near-normal life expectancy. However, a significant number of patients…”
    Get full text
    Journal Article